4. Intangible Assets, Goodwill and Other

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure

4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):


	2022						2021
	Life Science		Clinical Diagnostics		Total		Life Science		Clinical Diagnostics		Total
Balances as of January 1:
Goodwill	$	333.3	$	349.2	$	682.5	$	277.9	$	349.2	$	627.1
Accumulated impairment losses and write-offs	(41.8)		(293.4)		(335.2)		(41.8)		(293.4)		(335.2)
Goodwill, net	291.5		55.8		347.3		236.1		55.8		291.9

Acquisitions (see Note 2)	—		55.9		55.9		55.4		—		55.4


Foreign currency adjustments	—		3.3		3.3		—		—		—
Period increase, net	—		59.2		59.2		55.4		—		55.4

Balances as of December 31:
Goodwill	333.3		408.4		741.7		333.3		349.2		682.5
Accumulated impairment losses and write-offs	(41.8)		(293.4)		(335.2)		(41.8)		(293.4)		(335.2)
Goodwill, net	$	291.5	$	115.0	$	406.5	$	291.5	$	55.8	$	347.3

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):


	December 31, 2022
	Weighted-Average Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.02	$	104.7	$	(89.9)	$	14.8
Know how	2.75	166.2		(153.9)		12.3
Developed product technology	12.83	211.1		(121.6)		89.5
Licenses	5.84	59.0		(38.5)		20.5
Tradenames	6.56	6.1		(4.5)		1.6
Covenants not to compete	3.13	6.4		(4.0)		2.4


Total finite-lived intangible assets		553.5		(412.4)		141.1
In-process research and development		191.0		—		191.0
Total purchased intangible assets		$	744.5	$	(412.4)	$	332.1


	December 31, 2021
	Weighted-Average Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.27	$	111.8	$	(90.7)	$	21.1
Know how	3.75	171.6		(154.9)		16.7
Developed product technology	13.42	215.6		(115.6)		100.0
Licenses	6.79	64.9		(40.6)		24.3
Tradenames	7.33	6.3		(4.4)		1.9
Covenants not to compete	3.78	6.5		(2.9)		3.6


Total finite-lived intangible assets		576.7		(409.1)		167.6
In-process research and development		86.3		—		86.3
Total purchased intangible assets		$	663.0	$	(409.1)	$	253.9

Amortization expense related to purchased intangible assets for the years ended December 31, 2022, 2021 and 2020 was $24.9 million, $28.4 million and $27.5 million, respectively. Estimated future amortization expense (based on existing purchased finite-lived intangible assets) for the years ending December 31, 2023, 2024, 2025, 2026, 2027 and thereafter is $23.5 million, $20.7 million, $18.8 million, $13.8 million, $11.5 million, and $52.8 million, respectively.